Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/C3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/C3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/C3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/C3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/C3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/C3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/C3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/C3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19018002 | Colorectum | MSS | positive regulation of proteasomal protein catabolic process | 40/3467 | 114/18723 | 1.96e-05 | 4.19e-04 | 40 |
GO:00608282 | Colorectum | MSS | regulation of canonical Wnt signaling pathway | 74/3467 | 253/18723 | 1.99e-05 | 4.26e-04 | 74 |
GO:00068882 | Colorectum | MSS | endoplasmic reticulum to Golgi vesicle-mediated transport | 44/3467 | 130/18723 | 2.17e-05 | 4.60e-04 | 44 |
GO:00061642 | Colorectum | MSS | purine nucleotide biosynthetic process | 59/3467 | 191/18723 | 2.36e-05 | 4.97e-04 | 59 |
GO:19900902 | Colorectum | MSS | cellular response to nerve growth factor stimulus | 23/3467 | 53/18723 | 2.56e-05 | 5.31e-04 | 23 |
GO:00725222 | Colorectum | MSS | purine-containing compound biosynthetic process | 61/3467 | 200/18723 | 2.65e-05 | 5.46e-04 | 61 |
GO:00067542 | Colorectum | MSS | ATP biosynthetic process | 24/3467 | 57/18723 | 3.16e-05 | 6.29e-04 | 24 |
GO:19058972 | Colorectum | MSS | regulation of response to endoplasmic reticulum stress | 31/3467 | 82/18723 | 3.17e-05 | 6.29e-04 | 31 |
GO:00467182 | Colorectum | MSS | viral entry into host cell | 47/3467 | 144/18723 | 3.35e-05 | 6.56e-04 | 47 |
GO:00092062 | Colorectum | MSS | purine ribonucleoside triphosphate biosynthetic process | 27/3467 | 68/18723 | 3.68e-05 | 7.09e-04 | 27 |
GO:00619122 | Colorectum | MSS | selective autophagy | 27/3467 | 68/18723 | 3.68e-05 | 7.09e-04 | 27 |
GO:00017012 | Colorectum | MSS | in utero embryonic development | 99/3467 | 367/18723 | 3.71e-05 | 7.10e-04 | 99 |
GO:00301002 | Colorectum | MSS | regulation of endocytosis | 63/3467 | 211/18723 | 4.05e-05 | 7.66e-04 | 63 |
GO:00610141 | Colorectum | MSS | positive regulation of mRNA catabolic process | 32/3467 | 87/18723 | 4.49e-05 | 8.28e-04 | 32 |
GO:20012352 | Colorectum | MSS | positive regulation of apoptotic signaling pathway | 42/3467 | 126/18723 | 4.95e-05 | 8.97e-04 | 42 |
GO:00550762 | Colorectum | MSS | transition metal ion homeostasis | 45/3467 | 138/18723 | 4.99e-05 | 9.02e-04 | 45 |
GO:00611571 | Colorectum | MSS | mRNA destabilization | 31/3467 | 84/18723 | 5.44e-05 | 9.70e-04 | 31 |
GO:00159852 | Colorectum | MSS | energy coupled proton transport, down electrochemical gradient | 14/3467 | 26/18723 | 5.52e-05 | 9.78e-04 | 14 |
GO:00159862 | Colorectum | MSS | ATP synthesis coupled proton transport | 14/3467 | 26/18723 | 5.52e-05 | 9.78e-04 | 14 |
GO:00091422 | Colorectum | MSS | nucleoside triphosphate biosynthetic process | 31/3467 | 85/18723 | 7.07e-05 | 1.21e-03 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C3 | SNV | Missense_Mutation | novel | c.2800N>C | p.Glu934Gln | p.E934Q | P01024 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
C3 | SNV | Missense_Mutation | | c.1052C>T | p.Ser351Phe | p.S351F | P01024 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
C3 | SNV | Missense_Mutation | rs199911426 | c.4594N>T | p.Arg1532Trp | p.R1532W | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
C3 | SNV | Missense_Mutation | | c.4276N>A | p.Asp1426Asn | p.D1426N | P01024 | protein_coding | deleterious(0.01) | probably_damaging(0.929) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | | c.3803N>G | p.Ser1268Cys | p.S1268C | P01024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | | c.1376N>T | p.Ser459Leu | p.S459L | P01024 | protein_coding | tolerated(0.09) | possibly_damaging(0.599) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C3 | SNV | Missense_Mutation | novel | c.4408N>A | p.Glu1470Lys | p.E1470K | P01024 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C3 | SNV | Missense_Mutation | novel | c.3118G>C | p.Glu1040Gln | p.E1040Q | P01024 | protein_coding | tolerated(0.11) | benign(0.063) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
C3 | SNV | Missense_Mutation | novel | c.2782N>G | p.Ser928Ala | p.S928A | P01024 | protein_coding | tolerated(0.22) | benign(0.007) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C3 | SNV | Missense_Mutation | | c.1452N>T | p.Glu484Asp | p.E484D | P01024 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | Imprime PGG immunotherapeutic | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | 19025129 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | COMPSTATIN | COMPSTATIN | 25494040 |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | POT-4 | | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | APL-2 | PEGCETACOPLAN | |
718 | C3 | PROTEASE INHIBITOR, DRUGGABLE GENOME, CELL SURFACE | | clozapine | CLOZAPINE | 26503818 |